舌下减敏疗法治疗鳞茎过敏成效高

洛杉矶（路透社健康时事评论）12月21日电—据《变态反应，脑膜炎及免疫学年鉴》杂志11创刊号一篇媒体报道，舌下减敏麻醉药（SLIT）化疗蜜蜂诱发的消化道过敏成效高。“借助于SLIT减少溃疡的并发症及药物折扣，加大社会上经济开销，”比利时Genoa医学院Giovanni Passalacqua麻省理工学院说。“先前已经有加强施打麻醉药加大社会上开销，但这是首次对实用麻醉药（SLIT）顺利进行完全符合评估的结果。”Passalacqua麻省理工学院及其同事们对蜜蜂诱发的过敏性溃疡和脑膜炎治果顺利进行研究课题，评估借助于SLIT结合规范化疗及另行借助于规范化疗的费用及。研究课题职员媒体报道，SLIT使63.1%的病症病症加强，并预防性51.8%的病症显现出脑膜炎，而另行应用规范麻醉药显然使23.2%的病症病症加强，预防性28.9%的病症显现出脑膜炎。而且同规范化疗相比，SLIT的直接及间接花费原则上减低：SLIT病症化疗的总体花费低于东欧国家公共服务管理系统得出的4年末另行药物化疗花费，并且低于社会上公众得出的2年末另行药物化疗花费。“SLIT并不能算是加强施打麻醉药的竞争对手，” Passalacqua麻省理工学院解释说，“而是将其作为化疗步骤的另一选择。它第二大的灵活性在于其最优的安全性和病症的极易不能接受性。”“SLIT在美国仍未正式应用，尽管一些变态反应研究课题专家应用它（并且赢得了令人满意的结果），” Passalacqua麻省理工学院说。“欧洲情况完全不同，SLIT在很多东欧国家中会广泛应用（如比利时，德国，法国，西班牙，葡萄牙，埃及及捷克）。”近期的问题是SLIT仍未得到FDA的批准，“Passalacqua麻省理工学院补充道。“受到FDA赞成的流行病学正在顺利进行中会，并有望得到批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Bell Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

编者：蓝色未来世界